Pfizer Inflammation and Immunology strives to deliver breakthroughs that enable freedom from day-to-day suffering for people living with chronic inflammatory diseases, which can be debilitating, disfiguring, and distressing. LITFULO, is a JAK3/TEC inhibitor that received approval in June 2023 and was the first FDA-approved treatment for severe AA in adolescents (ages 12-17) and adults. Currently, there are three, FDA-approved medicine for severe AA, with new competitors entering the market starting in 2027. The US LITFULO team comprises a group of talented, diverse, tenacious colleagues and attracts employees focused on developing or enhancing their growth mindset. With several Pfizer Firsts under our belt, we remain focused on building an excellent, innovative brand with patients at the center of our mission. The team is driven by an unrelenting determination to embody Pfizer’s values and to be the catalyst for every team member’s success. We harness our individual and collective strengths and embrace the courage to pursue boldness. The LITFULO HCP Director is a crucial role that will lead all field force marketing efforts and support the strategy and execution of key HCP-focused resources. This high-visibility position will support key go-to-market milestones with strategic and tactical focus. This position will report to the US LITFULO Brand Lead and will work closely with cross-functional colleagues and external vendors.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Senior